Interleukin-2 continuous infusion and angiogenesis surrogate markers in metastatic renal cell carcinoma.
C
C
Simonelli
R
R
Talamini
A
A
Bearz
M
M
Berretta
S
S
Spazzapan
P
P
Monini
C
C
Sgadari
I
I
Sartor
B
B
Ensoli
U
U
Tirelli
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis / Q000378:metabolism; D002292:Carcinoma, Renal Cell / Q000098:blood supply / Q000188:drug therapy* / Q000556:secondary; D016207:Cytokines / Q000032:analysis / Q000378:metabolism; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D015415:Biomarkers; D016207:Cytokines; D007376:Interleukin-2